Recombinetics leverages all aspects of the company to offer complete pre-clinical solutions to gene therapy development. As experts in genome editing in livestock, we offer a range of swine models that feature targetable genetic diseases, as well as novel reporter animals to accelerate the journey from bench-top to bedside.
Recombinetics has developed a method to derive and maintain stable porcine-induced pluripotent and embryonic stem cells, building on its success with bovine stem cells for agricultural applications through Acceligen. Porcine stem cells, valued for their self-renewal and differentiation potential, fill a gap in the stem cell and disease modeling market, with applications in regenerative medicine, tissue engineering, drug development, and reproductive biotechnologies.